# Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

Study · id `cardio:ct-nct03700645` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03700645](<https://clinicaltrials.gov/study/NCT03700645>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03700645

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03700645. Randomized; no masking; primary purpose prevention. Start 2018-12-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03700645, source copy `cardio:ctgov-nct03700645-2018-11-21`, retrieved 2026-10-26)
- Planned start: 2018-12-01 (anticipated) (ClinicalTrials.gov record NCT03700645, source copy `cardio:ctgov-nct03700645-2018-11-21`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03700645, source copy `cardio:ctgov-nct03700645-2018-11-21`, retrieved 2026-10-26)
- Completion: 2020-01-31 (anticipated) (ClinicalTrials.gov record NCT03700645, source copy `cardio:ctgov-nct03700645-2018-11-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03700645-2018-11-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease
- Condition: Diabetes Mellitus
- Condition: Ischemic Heart Disease
- Condition: Multi Vessel Coronary Artery Disease
- Intervention (Drug): Allopurinol
- Lead sponsor: Tel-Aviv Sourasky Medical Center
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Tel-Aviv Sourasky Medical Center (`cardio:org-tel-aviv-sourasky-medical-center`)

## Provenance

Content hash: c0da34ab00c27940562298aa5919b4cabe05861254e24750ebb0e92015618417
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
